Answers are grounded in this paper and cite their sources.
This review examines how probiotics modulate inflammation, highlighting challenges and future strategies for applications in health.
Probiotic-derived immunomodulation represents a paradigm shift in managing inflammatory disorders, offering unprecedented opportunities to restore immune homeostasis and combat inflammation-driven pathologies. Despite their therapeutic promise, the clinical translation of probiotics has been hindered by an incomplete mechanistic understanding of their pleiotropic effects. This review systematically delineates the multifaceted anti-inflammatory mechanisms of probiotics, encompassing the reconstruction of gut microbial ecosystems, modulation of immune regulatory circuits, mitigation of oxidative stress, and disruption of pro-inflammatory signaling pathways. Translational advances encompassing gnotobiotic models, randomized controlled trials, and bioengineered probiotics harboring enhanced therapeutic payloads are rigorously evaluated in this review. A systematic examination of industrial applications in nutraceuticals, pharmaceuticals, and functional foods is presented, alongside a critical discussion of persistent translational bottlenecks. Looking forward, we emphasize multi-omics-guided strain discovery, synthetic biology-based engineering of intelligent microbial therapeutics, and optimized translational frameworks to unlock the full potential of microbiota-targeted immunomodulation in precision medicine.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: